Study of Alogliptin Combined With Sulfonylurea in Subjects With Type 2 Diabetes Mellitus.

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Takeda
ClinicalTrials.gov Identifier:
NCT00286468
First received: February 1, 2006
Last updated: February 1, 2012
Last verified: February 2012

February 1, 2006
February 1, 2012
April 2006
June 2007   (final data collection date for primary outcome measure)
Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26. [ Time Frame: Baseline and Week 26. ] [ Designated as safety issue: No ]
The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 26 or final visit and glycosylated hemoglobin collected at baseline.
Change in HbA1c at end of study
Complete list of historical versions of study NCT00286468 on ClinicalTrials.gov Archive Site
  • Change From Baseline in Glycosylated Hemoglobin (Week 4). [ Time Frame: Baseline and Week 4. ] [ Designated as safety issue: No ]
    The change in the value of Glycosylated Hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 4 and Glycosylated Hemoglobin collected at baseline.
  • Change From Baseline in Glycosylated Hemoglobin (Week 8). [ Time Frame: Baseline and Week 8. ] [ Designated as safety issue: No ]
    The change in the value of Glycosylated Hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 8 and Glycosylated Hemoglobin collected at baseline.
  • Change From Baseline in Glycosylated Hemoglobin (Week 12). [ Time Frame: Baseline and Week 12. ] [ Designated as safety issue: No ]
    The change in the value of Glycosylated Hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 12 and Glycosylated Hemoglobin collected at baseline.
  • Change From Baseline in Glycosylated Hemoglobin (Week 16). [ Time Frame: Baseline and Week 16. ] [ Designated as safety issue: No ]
    The change in the value of Glycosylated Hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 16 and Glycosylated Hemoglobin collected at baseline.
  • Change From Baseline in Glycosylated Hemoglobin (Week 20). [ Time Frame: Baseline and Week 20. ] [ Designated as safety issue: No ]
    The change in the value of Glycosylated Hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 20 and Glycosylated Hemoglobin collected at baseline.
  • Change From Baseline in Fasting Plasma Glucose (Week 1). [ Time Frame: Baseline and Week 1. ] [ Designated as safety issue: No ]
    The change between the value of fasting plasma glucose collected at final visit or week 1 and fasting plasma glucose collected at baseline.
  • Change From Baseline in Fasting Plasma Glucose (Week 2). [ Time Frame: Baseline and Week 2. ] [ Designated as safety issue: No ]
    The change between the value of fasting plasma glucose collected at week 2 and fasting plasma glucose collected at baseline.
  • Change From Baseline in Fasting Plasma Glucose (Week 4). [ Time Frame: Baseline and Week 4. ] [ Designated as safety issue: No ]
    The change between the value of fasting plasma glucose collected at week 4 and fasting plasma glucose collected at baseline.
  • Change From Baseline in Fasting Plasma Glucose (Week 8). [ Time Frame: Baseline and Week 8. ] [ Designated as safety issue: No ]
    The change between the value of fasting plasma glucose collected at week 8 and fasting plasma glucose collected at baseline.
  • Change From Baseline in Fasting Plasma Glucose (Week 12). [ Time Frame: Baseline and Week 12. ] [ Designated as safety issue: No ]
    The change between the value of fasting plasma glucose collected at week 12 and fasting plasma glucose collected at baseline.
  • Change From Baseline in Fasting Plasma Glucose (Week 16). [ Time Frame: Baseline and Week 16. ] [ Designated as safety issue: No ]
    The change between the value of fasting plasma glucose collected at week 16 and fasting plasma glucose collected at baseline.
  • Change From Baseline in Fasting Plasma Glucose (Week 20). [ Time Frame: Baseline and Week 20. ] [ Designated as safety issue: No ]
    The change between the value of fasting plasma glucose collected at week 20 and fasting plasma glucose collected at baseline.
  • Change From Baseline in Fasting Plasma Glucose (Week 26). [ Time Frame: Baseline and Week 26. ] [ Designated as safety issue: No ]
    The change between the value of fasting plasma glucose collected at week 26 or final visit and fasting plasma glucose collected at baseline.
  • Number of Participants With Marked Hyperglycemia (Fasting Plasma Glucose ≥ 200 mg Per dL). [ Time Frame: 26 Weeks. ] [ Designated as safety issue: No ]
    The number of participants with a fasting plasma glucose value greater than or equal to 200 mg per dL during the 26 week study.
  • Number of Participants Requiring Rescue. [ Time Frame: 26 Weeks. ] [ Designated as safety issue: No ]
    The number of participants requiring rescue for failing to achieve pre-specified glycemic targets during the 26 week study.
  • Change From Baseline in Fasting Proinsulin (Week 4). [ Time Frame: Baseline and Week 4. ] [ Designated as safety issue: No ]
    The change between the value of fasting proinsulin collected at week 4 and fasting proinsulin collected at baseline.
  • Change From Baseline in Fasting Proinsulin (Week 8). [ Time Frame: Baseline and Week 8. ] [ Designated as safety issue: No ]
    The change between the value of fasting proinsulin collected at week 8 and fasting proinsulin collected at baseline.
  • Change From Baseline in Fasting Proinsulin (Week 12). [ Time Frame: Baseline and Week 12. ] [ Designated as safety issue: No ]
    The change between the value of fasting proinsulin collected at week 12 and fasting proinsulin collected at baseline.
  • Change From Baseline in Fasting Proinsulin (Week 16). [ Time Frame: Baseline and Week 16. ] [ Designated as safety issue: No ]
    The change between the value of fasting proinsulin collected at week 16 and fasting proinsulin collected at baseline.
  • Change From Baseline in Fasting Proinsulin (Week 20). [ Time Frame: Baseline and Week 20. ] [ Designated as safety issue: No ]
    The change between the value of fasting proinsulin collected at week 20 and fasting proinsulin collected at baseline.
  • Change From Baseline in Fasting Proinsulin (Week 26). [ Time Frame: Baseline and Week 26. ] [ Designated as safety issue: No ]
    The change between the value of fasting proinsulin collected at week 26 or final visit and fasting proinsulin collected at baseline.
  • Change From Baseline in Insulin (Week 4). [ Time Frame: Baseline and Week 4. ] [ Designated as safety issue: No ]
    The change between the value of insulin collected at week 4 and insulin collected at baseline.
  • Change From Baseline in Insulin (Week 8). [ Time Frame: Baseline and Week 8. ] [ Designated as safety issue: No ]
    The change between the value of insulin collected at week 8 and insulin collected at baseline.
  • Change From Baseline in Insulin (Week 12). [ Time Frame: Baseline and Week 12. ] [ Designated as safety issue: No ]
    The change between the value of insulin collected at week 12 and insulin collected at baseline.
  • Change From Baseline in Insulin (Week 16). [ Time Frame: Baseline and Week 16. ] [ Designated as safety issue: No ]
    The change between the value of insulin collected at week 16 and insulin collected at baseline.
  • Change From Baseline in Insulin (Week 20). [ Time Frame: Baseline and Week 20. ] [ Designated as safety issue: No ]
    The change between the value of insulin collected at week 20 and insulin collected at baseline.
  • Change From Baseline in Insulin (Week 26). [ Time Frame: Baseline and Week 26. ] [ Designated as safety issue: No ]
    The change between the value of insulin collected at week 26 and insulin collected at baseline.
  • Change From Baseline in Proinsulin/Insulin Ratio (Week 4). [ Time Frame: Baseline and Week 4. ] [ Designated as safety issue: No ]
    The change between the ratio value of proinsulin and insulin collected at week 4 and the ratio value of proinsulin and insulin collected at baseline.
  • Change From Baseline in Proinsulin/Insulin Ratio (Week 8). [ Time Frame: Baseline and Week 8. ] [ Designated as safety issue: No ]
    The change between the ratio value of proinsulin and insulin collected at week 8 and the ratio value of proinsulin and insulin collected at baseline.
  • Change From Baseline in Proinsulin/Insulin Ratio (Week 12). [ Time Frame: Baseline and Week 12. ] [ Designated as safety issue: No ]
    The change between the ratio value of proinsulin and insulin collected at week 12 and the ratio value of proinsulin and insulin collected at baseline.
  • Change From Baseline in Proinsulin/Insulin Ratio (Week 16). [ Time Frame: Baseline and Week 16. ] [ Designated as safety issue: No ]
    The change between the ratio value of proinsulin and insulin collected at week 16 and the ratio value of proinsulin and insulin collected at baseline.
  • Change From Baseline in Proinsulin/Insulin Ratio (Week 20). [ Time Frame: Baseline and Week 20. ] [ Designated as safety issue: No ]
    The change between the ratio value of proinsulin and insulin collected at week 20 and the ratio value of proinsulin and insulin collected at baseline.
  • Change From Baseline in Proinsulin/Insulin Ratio (Week 26). [ Time Frame: Baseline and Week 26. ] [ Designated as safety issue: No ]
    The change between the ratio value of proinsulin and insulin collected at week 26 or final visit and the ratio value of proinsulin and insulin collected at baseline.
  • Change From Baseline in C-peptide (Week 4). [ Time Frame: Baseline and Week 4. ] [ Designated as safety issue: No ]
    The change between the value of C-peptide collected at week 4 and C-peptide collected at baseline.
  • Change From Baseline in C-peptide (Week 8). [ Time Frame: Baseline and Week 8. ] [ Designated as safety issue: No ]
    The change between the value of C-peptide collected at week 8 and C-peptide collected at baseline.
  • Change From Baseline in C-peptide (Week 12). [ Time Frame: Baseline and Week 12. ] [ Designated as safety issue: No ]
    The change between the value of C-peptide collected at week 12 and C-peptide collected at baseline.
  • Change From Baseline in C-peptide (Week 16). [ Time Frame: Baseline and Week 16. ] [ Designated as safety issue: No ]
    The change between the value of C-peptide collected at week 16 and C-peptide collected at baseline.
  • Change From Baseline in C-peptide (Week 20). [ Time Frame: Baseline and Week 20. ] [ Designated as safety issue: No ]
    The change between the value of C-peptide collected at week 20 and C-peptide collected at baseline.
  • Change From Baseline in C-peptide (Week 26). [ Time Frame: Baseline and Week 26. ] [ Designated as safety issue: No ]
    The change between the value of C-peptide collected at week 26 or final visit and C-peptide collected at baseline.
  • Number of Participants With Glycosylated Hemoglobin ≤ 6.5%. [ Time Frame: Baseline and Week 26. ] [ Designated as safety issue: No ]
    The number of participants with a value for the percentage of glycosylated hemoglobin (the percentage of hemoglobin that is bound to glucose) less than or equal to 6.5% during the 26 week study.
  • Number of Participants With Glycosylated Hemoglobin ≤ 7.0%. [ Time Frame: Baseline and Week 26. ] [ Designated as safety issue: No ]
    The number of participants with a value for the percentage of glycosylated hemoglobin (the percentage of hemoglobin that is bound to glucose) less than or equal to 7.0% during the 26 week study.
  • Number of Participants With Glycosylated Hemoglobin ≤ 7.5%. [ Time Frame: Baseline and Week 26. ] [ Designated as safety issue: No ]
    The number of participants with a value for the percentage of glycosylated hemoglobin (the percentage of hemoglobin that is bound to glucose) less than or equal to 7.5% during the 26 week study.
  • Number of Participants With Glycosylated Hemoglobin Decrease From Baseline ≥ 0.5%. [ Time Frame: Baseline and Week 26. ] [ Designated as safety issue: No ]
    The number of participants with a decrease from baseline in the percentage of glycosylated hemoglobin (the percentage of hemoglobin that is bound to glucose) greater than or equal to 0.5% during the 26 week study.
  • Number of Participants With Glycosylated Hemoglobin Decrease From Baseline ≥ 1.0%. [ Time Frame: Baseline and Week 26. ] [ Designated as safety issue: No ]
    The number of participants with a decrease from baseline in the percentage of glycosylated hemoglobin (the percentage of hemoglobin that is bound to glucose) greater than or equal to 1.0% during the 26 week study.
  • Number of Participants With Glycosylated Hemoglobin Decrease From Baseline ≥ 1.5%. [ Time Frame: Baseline and Week 26. ] [ Designated as safety issue: No ]
    The number of participants with a decrease from baseline in the percentage of glycosylated hemoglobin (the percentage of hemoglobin that is bound to glucose) greater than or equal to 1.5% during the 26 week study.
  • Number of Participants With Glycosylated Hemoglobin Decrease From Baseline ≥ 2.0%. [ Time Frame: Baseline and Week 26. ] [ Designated as safety issue: No ]
    The number of participants with a decrease from baseline in the percentage of glycosylated hemoglobin (the percentage of hemoglobin that is bound to glucose) greater than or equal to 2.0% during the 26 week study.
  • Change From Baseline in Body Weight (Week 8). [ Time Frame: Baseline and Week 8. ] [ Designated as safety issue: No ]
    The change between Body Weight measured at week 8 and Body Weight measured at baseline.
  • Change From Baseline in Body Weight (Week 12). [ Time Frame: Baseline and Week 12. ] [ Designated as safety issue: No ]
    The change between Body Weight measured at week 12 and Body Weight measured at baseline.
  • Change From Baseline in Body Weight (Week 20). [ Time Frame: Baseline and Week 20. ] [ Designated as safety issue: No ]
    The change between Body Weight measured at week 20 and Body Weight measured at baseline.
  • Change From Baseline in Body Weight (Week 26). [ Time Frame: Baseline and Week 26. ] [ Designated as safety issue: No ]
    The change between Body Weight measured at week 26 or final visit and Body Weight measured at baseline.
Not Provided
Not Provided
Not Provided
 
Study of Alogliptin Combined With Sulfonylurea in Subjects With Type 2 Diabetes Mellitus.
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of SYR110322 (SYR-322) When Used in Combination With a Sulfonylurea in Subjects With Type 2 Diabetes

The purpose of this study is to evaluate the efficacy and safety of alogliptin, once daily (QD), combined with a sulfonylurea in adults with type 2 diabetes mellitus.

There are approximately 19 million people in the United States who have been diagnosed with diabetes mellitus, of which 90% to 95% are type 2. The prevalence of type 2 diabetes varies among racial and ethnic populations and has been shown to correlate with age, obesity, family history, history of gestational diabetes, and physical inactivity. Over the next decade, a marked increase in the number of adults with diabetes mellitus is expected.

Takeda is developing SYR-322 (alogliptin) for the improvement of glycemic control in patients with type 2 diabetes mellitus. Alogliptin is an inhibitor of the dipeptidyl peptidase IV enzyme. Dipeptidyl peptidase IV is thought to be primarily responsible for the degradation of 2 peptide hormones released in response to nutrient ingestion. It is expected that inhibition of dipeptidyl peptidase IV will improve glycemic (glucose) control in patients with type 2 diabetes.

The aim of the current study is to evaluate the effectiveness of alogliptin in combination with a sulfonylurea in subjects who are inadequately controlled on a sulfonylurea alone. Individuals who participate in this study will be required to commit to a screening visit and up to 14 additional visits at the study center. Study participation is anticipated to be about 34 weeks (or 8.5 months).

Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Diabetes Mellitus
  • Drug: Alogliptin and glyburide
    Alogliptin 12.5 mg, tablets, orally, once daily and glyburide for up to 26 weeks.
    Other Names:
    • alogliptin
    • SYR110322
    • SYR-322
  • Drug: Alogliptin and glyburide
    Alogliptin 25 mg, tablets, orally, once daily and glyburide for up to 26 weeks.
    Other Names:
    • alogliptin
    • SYR110322
    • SYR-322
  • Drug: Glyburide
    Alogliptin placebo-matching tablets, orally, once daily and glyburide for up to 26 weeks.
  • Experimental: Alogliptin 12.5 mg QD
    Intervention: Drug: Alogliptin and glyburide
  • Experimental: Alogliptin 25 mg QD
    Intervention: Drug: Alogliptin and glyburide
  • Active Comparator: Placebo
    Intervention: Drug: Glyburide

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
500
June 2007
June 2007   (final data collection date for primary outcome measure)

Inclusion Criteria

  • Diagnosis of type 2 diabetes mellitus , currently treated with a sulfonylurea alone but experiencing inadequate glycemic control. Should have received the sulfonylurea monotherapy for at least the 3 months prior to Screening; has been on a stable sulfonylurea dose equivalent to at least 10 mg of glyburide (Exception: documented maximum tolerated dose equivalent to less than 10 mg but at least 5 mg glyburide) for at least 8 weeks.
  • No treatment with antidiabetic agents other than a sulfonylurea within the 3 months prior to Screening. (Exception: if a subject has received other antidiabetic therapy for less than 7 days within the 3 months prior to Screening.)
  • Body mass index greater than or equal to 23 kg/m2 and less than or equal to 45 kg/m2.
  • Fasting C-peptide concentration greater than or equal to 0.8 ng/mL. (If this screening criterion is not met, the subject still qualifies if C-peptide is greater than or equal to 1.5 ng/mL after a challenge test.).
  • Glycosylated hemoglobin concentration between 7.0% and 10.0%, inclusive.
  • If regular use of other, non-excluded medications, must be on a stable dose for at least the 4 weeks prior to Screening. However, as needed use of prescription or over-the-counter medications is allowed at the discretion of the investigator.
  • Systolic blood pressure less than or equal to180 mm Hg and diastolic pressure less than or equal to 110 mm Hg
  • Hemoglobin greater than or equal to 12 g per dL for males and greater than or equal to 10 g per dL for females
  • Alanine aminotransferase less than or equal to 3 time the upper limit of normal.
  • Serum creatinine ≤2.0 mg/dL (≤17 micromol/L)
  • Thyroid-stimulating hormone level less than or equal to the upper limit of the normal range and the subject is clinically euthyroid.
  • Neither pregnant nor lactating
  • Female subjects of childbearing potential must be practicing adequate contraception. Adequate contraception must be practiced for the duration of participation in the study.
  • Able and willing to monitor their own blood glucose concentrations with a home glucose monitor.
  • No major illness or debility that in the investigator's opinion prohibits the subject from completing the study.
  • Able and willing to provide written informed consent

Exclusion Criteria

  • Urine albumin to creatinine ratio of greater than 1000 μg per mg at Screening. If elevated, the subject may be rescreened within 1 week.
  • History of cancer, other than squamous cell or basal cell carcinoma of the skin, that has not been in full remission for at least 5 years prior to Screening. (A history of treated cervical intraepithelial neoplasia I or cervical intraepithelial neoplasia II is allowed.)
  • History of laser treatment for proliferative diabetic retinopathy within the 6 months prior to Screening.
  • History of treated diabetic gastric paresis.
  • New York Heart Association Class III or IV heart failure regardless of therapy. Currently treated subjects who are stable at Class I or II are candidates for the study.
  • History of coronary angioplasty, coronary stent placement, coronary bypass surgery, or myocardial infarction within the 6 months prior to Screening.
  • History of any hemoglobinopathy that may affect determination of glycosylated hemoglobin.
  • History of infection with hepatitis B, hepatitis C, or human immunodeficiency virus.
  • History of a psychiatric disorder that will affect the subject's ability to participate in the study.
  • History of angioedema in association with use of angiotensin-converting enzyme inhibitors or angiotensin-II receptor inhibitors.
  • History of alcohol or substance abuse within the 2 years prior to Screening.
  • Receipt of any investigational drug within the 30 days prior to Screening or a history of receipt of an investigational antidiabetic drug within the 3 months prior to Screening.
  • Prior treatment in an investigational study of alogliptin.
  • Excluded Medications and Treatments:

    • Treatment with antidiabetic agents other than study drug or glyburide is not allowed within the 3 months prior to Screening and through the completion of the end-of-treatment/early termination procedures.
    • Treatment with weight-loss drugs, any investigational antidiabetics, Bosentan (used for the treatment of pulmonary hypertension), or oral or systemically injected glucocorticoids is not allowed from 3 months prior to randomization through the completion of the end-of- treatment/early termination procedures. Inhaled corticosteroids are allowed.
    • Subjects must not take any medications, including over-the-counter products, without first consulting with the investigator.
Both
18 Years to 80 Years
No
Contact information is only displayed when the study is recruiting subjects
United States,   Argentina,   Australia,   Brazil,   Chile,   Dominican Republic,   Guatemala,   India,   Mexico,   Netherlands,   New Zealand,   Peru,   Poland,   South Africa,   United Kingdom
 
NCT00286468
SYR-322-SULF-007, 2005-004667-36, U1111-1113-8506
No
Takeda
Takeda
Not Provided
Study Director: VP Biological Sciences Takeda
Takeda
February 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP